Obesity evidence dossier
Zenagamtide (amycretin)
Important to watch because amylin plus GLP-1 could become a major next-generation obesity approach if tolerability and durability hold up. Now in Phase 3, but no pivotal obesity efficacy figure is yet available to rank.
Total weight loss
24.3%
NN9490-7613 · 60 mg weekly, dose escalation · week 36 · Analysis not fully specified
Placebo-adjusted
23.2%
Difference from placebo in the same study when reported.
Study context
GLP-1/amylin co-agonist/Adults with obesity or overweight, without diabetes/125 participants across the study/36-week endpoint
Baseline: See the source for enrollment criteria
Ranked result & calculation
NN9490-7613 · 60 mg weekly, dose escalation · 36 weeks
Adults with obesity or overweight, without diabetes. 125 participants across the study (not this dose arm alone).
Analysis not fully specified. The source does not establish a treatment-policy analysis; interpret this score provisionally. Estimated change in the 60 mg dose-escalation arm; treatment-policy status is not established in this presentation.
- Average weight loss
- 24.3%
- Placebo group
- 1.1% loss
- Beyond placebo
- 23.2 percentage points (arm subtraction)
- Stopped due to adverse events
- Not verified for this result
Early dose-escalation cohort; 125 is total study enrollment, not the size of this arm.
Score: 70% × 93.2 total-loss points + 30% × 95.1 beyond-placebo points = 94/100, rounded. Conversion scales
Novo Nordisk, Q2 2026 trial presentation ↗Phase 1b/2a · Sponsor disclosure · Reviewed 2026-09-21
Evidence
Benchmark read
NN9490-7613: Analysis not fully specified. Estimated change in the 60 mg dose-escalation arm; treatment-policy status is not established in this presentation. Early dose-escalation cohort; 125 is total study enrollment, not the size of this arm.
Diabetes data
Diabetes cohorts should be separated because glycemic status can materially change observed weight loss.
Safety
Side effects and cautions
Discontinuation read
Adverse-event discontinuation has not been verified for this result.
Common side effects
Gastrointestinal tolerability is the main expected watch item for GLP-1 and amylin-based escalation.
Main cautions
Not approved; the ~22% figure is an early 36-week adherence-based estimate at 20 mg subcutaneous, not a pivotal result. Dose selection and discontinuation rates in Phase 3 remain to be reported.
Upcoming catalyst
What to watch next
AMAZE Phase 3 readouts, dose strategy, and oral-versus-injectable positioning.
Linked clinical trials
Trials in the saddl3 obesity snapshot
Non-diabetic obesity studies are prioritized; diabetes and healthy-volunteer studies remain visible and labeled.
NCT06049329
Phase 1
A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity
Novo Nordisk A/S
Non-diabetic obesity
Mar 5, 2025
NCT07503210
Phase 3
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
Novo Nordisk A/S
Other obesity study
Mar 31, 2026
NCT07400107
Phase 3
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Novo Nordisk A/S
Type 2 diabetes / obesity
Mar 12, 2026